ABSTRACT
Importance With the implementation of Measure 110 (M110), Oregon became the first state in the United States to decriminalize small amounts of any drugs for personal use. No analysis of the effect of this law on overdose mortality has fully accounted for the introduction of fentanyl to Oregon’s unregulated drug market, a substance known to drive fatal overdose rates.
Objective To evaluate whether the decriminalization of drug possession in Oregon was associated with changes in fatal drug overdose rates after accounting for the rapid escalation of fentanyl in Oregon’s unregulated drug market.
Design, Setting, and Participants The association between fatal drug overdose and enactment of M110 was analyzed using a matrix completion synthetic control method. The control group consisted of the 48 US states and Washington DC that did not decriminalize drugs. The rapid escalation of fentanyl in unregulated drug markets was determined using the state-level percentage of all samples reported to the National Forensic Laboratory Information System that were identified as fentanyl or its analogs. A changepoint analysis was used to determine when each state experienced a rapid escalation of fentanyl in its unregulated drug market, which was included as a covariate. Mortality data were obtained from the Centers for Disease Control and Prevention from 2008-2022.
Exposures M110 took effect on February 1, 2021.
Main Outcome Fatal drug overdose rates per half-year.
Results Analysis indicated a rapid escalation of fentanyl in Oregon’s unregulated drug supply occurred in the first half of 2021, contemporaneous with enactment of M110. The crude association between decriminalization and fatal overdose rate per 100,000 per half-year was significant (Tau = 1.83; SE = 0.39; p < 0.001); however, adjusting for rapid escalation of fentanyl as a confounder, the effect of drug decriminalization on overdose mortality in Oregon was null (Tau = −0.51; SE = 0.36). Sensitivity analyses were consistent with this result.
Conclusions and Relevance After adjusting for the rapid escalation of fentanyl, analysis found no association between M110 and fatal drug overdose rates. Future evaluations of the health effects of drug policies should account for changes in the composition of unregulated drug markets.
Question What was the association between the Oregon’s 2021 law that decriminalized drug possession and overdose mortality when accounting for the spread of fentanyl through the state’s unregulated drug market?
Findings In this longitudinal synthetic control study, fentanyl’s rapid spread through Oregon’s unregulated drug market occurred contemporaneously with the state’s decriminalization of drug possession. An analysis that accounted for fentanyl’s introduction to the drug supply showed that decriminalization was not associated with an increase in fatal drug overdose rates in Oregon in the two years after its enactment.
Meaning When evaluating the effect of public policies on overdose mortality, it is critical to account for the role of fentanyl as the principal driver of the nation’s overdose mortality epidemic. After accounting for the spread of fentanyl to Oregon, there was no association between decriminalizing drug possession and changes in the state’s fatal drug overdose rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by the National Institute on Drug Abuse (K01DA056654 to Dr. del Pozo) and Arnold Ventures (grant funding to Drs. Kral and Lambdin). These organizations had no role in the conduct of the study, nor the preparation of this manuscript, and the findings and opinions expressed do not necessarily reflect their views or positions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data were publicly available prior to the initiation of our study. They are available for download from the Centers for Disease Control and Prevention, and the US Drug Enforcement Administration's National Forensic Laboratory Information System, via their websites: https://wonder.cdc.gov/ and https://www.nflis.deadiversion.usdoj.gov/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revision adds figures referenced in the text but that did not accompany the original preprint.
Data Availability
All data produced are available online at https://wonder.cdc.gov/ and https://www.nflis.deadiversion.usdoj.gov/
